Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
Go back to Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference| (NASDAQ: TBPH) | Delayed: 16.81 +0.23 (1.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.58 | 52 Week High | $38.92 | |||
| Open | $16.72 | 52 Week Low | $12.87 | |||
| Day High | $16.88 | P/E | N/A | |||
| Day Low | $16.41 | EPS | $0.00 | |||
| Volume | 257,559 | |||||
